2-mercaptoethane
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2023 (NCT05882604)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- Unspecified targetINHIBITOR
acrolein
Chemistry & pharmacology
Loading structure…
SMILES
O=S(=O)(O)CCS- Mol. weight
- 142.2 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1098319 ↗
Also known as
- 2-mercaptoethane
- 2-mercaptoethane
- 2-mercaptoethane
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07255664 | Phase 1/Phase 2 (Phase 2) | Nov 13, 2025 | Curacell Holding AB, Institut für Klinische Krebsforschung IKF GmbH |
| NCT05882604 | N/A | May 1, 2023 | Tanta University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Curacell Holding AB | For profit | 1 | 1 | 1 | 2025 |
| Institut für Klinische Krebsforschung IKF GmbH | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Tanta University | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1